Presentation June 2020 DISCLAIMERS AND FORWARD-LOOKING STATEMENTS - - PowerPoint PPT Presentation

presentation
SMART_READER_LITE
LIVE PREVIEW

Presentation June 2020 DISCLAIMERS AND FORWARD-LOOKING STATEMENTS - - PowerPoint PPT Presentation

Investor Presentation June 2020 DISCLAIMERS AND FORWARD-LOOKING STATEMENTS Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the


slide-1
SLIDE 1

Investor Presentation

June 2020

slide-2
SLIDE 2

Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” “could,” “appears,” “shall,” “target,” “contemplated,” “predicts,” “potential,” “continue” and variations and negatives of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have

  • made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking

statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, statements about our future financial performance and ability to achieve profitability, including our revenue, costs of revenue and operating expenses; our anticipated growth and growth strategies and our ability to effectively manage that growth; the sufficiency of our cash, cash equivalents and investments to meet our liquidity needs; our ability to maintain the security and availability of our platform; our predictions about our industry (including total addressable market) and market trends for healthcare technology solutions; our ability to attract, retain and cross-sell to healthcare provider clients; our ability to maintain renewal rates for healthcare provider clients; our ability to maintain, protect and enhance our intellectual property; our ability to comply with modified or new laws and regulations applying to our business; the increased expenses associated with being a public company; and our outstanding debt under our credit facility, as well as those set forth in our Annual Report on Form 10-K that was filed with the SEC on April 23, 2020 and our other filings with the U.S. Securities and Exchange Commission, including “Risk Factors” sections contained therein. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. This presentation may include certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, which is available in the Appendix.

DISCLAIMERS AND FORWARD-LOOKING STATEMENTS

2

slide-3
SLIDE 3

3

How we do it: Software-as-a-Service (SaaS) platform to manage the patient intake process and an integrated patient payments solution for secure processing of patient payments

~1,600 healthcare

provider organizations

is Patient Intake

$1.9B

patient payments processed in FY20

Who we are: Leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care

$125M

revenue in FY20

25% revenue

growth in FY20

What we do: Enable healthcare provider organizations to optimize

  • perational efficiency, improve profitability and enhance clinical care

~$7B total

addressable market

slide-4
SLIDE 4

Leadership in large, underpenetrated and growing market with strong tailwinds Proven ability to innovate and meet the evolving needs of our clients

INVESTMENT HIGHLIGHTS

4

Leading SaaS platform for patient intake and experience with integrated patient payments Attractive, highly scalable financial model Significant and measurable return on investment Founder-led and deeply experienced management team with strong culture Multiple growth opportunities

slide-5
SLIDE 5

ATTRACTIVE INDUSTRY TAILWINDS

5

Wasteful Spending Increasing Patient Responsibility Increasing Consumerism Shift to Value-Based Care Models

  • $586B out-of-

pocket spend by 2027

  • HDHPs represent

46% of health plan market2

  • Provider
  • rganizations

collect only half of patient balances after initial visit

  • Demand for higher

quality care, cost transparency, shared decision making and convenience

  • 70%+ of patients

use online reviews as first step in physician search

  • Payment model

shift to incentivize value and quality

  • Requires high levels
  • f documentation,

robust data, sophisticated payment-attribution capabilities and substantive patient engagement

Focus on Personalized Healthcare Solutions

  • Need to directly

reach patients when making care decisions

  • Current marketing

strategies not as effective as targeted outreach

  • 1.2M intake staff
  • $3.6T U.S.

healthcare spend1

  • $1.1T U.S.

healthcare waste1

  • ~$300B admin-

related waste1

1 In 2018 2 As of the first half of 2018
slide-6
SLIDE 6

OUR VALUE PROPOSITION AND HOW WE MAKE MONEY

6

Providers

  • Simplified operations & enhanced

staff efficiency

  • Improved cash flow and

profitability

  • Enhanced clinical quality
  • Improved patient experience
  • Highly visible subscription fees

charged on a per provider per month basis (PMPM)

  • Based on number and type of

applications elected

Patients

  • Improved patient experience
  • High patient usage
  • Flexible payment options
  • Engagement in care
  • Re-occurring payment processing

fees

  • Based on level of patient payment

volume processed through Phreesia Platform

Life Sciences Companies

  • Targeted, direct digital marketing
  • Improved brand conversion and

adherence

  • Feedback from patient voice
  • Fees from the sale of digital

marketing solutions to life sciences companies

  • Based on guaranteed number of

engagements with target audiences Value proposition How we make money

slide-7
SLIDE 7

Staff Use These:

IN THE OFFICE Phreesia Dashboard AT HOME, ON THE GO, IN THE OFFICE Mobile IN THE OFFICE PhreesiaPad Arrivals Station

Patients Use These:

IN THE OFFICE Analytics

OUR END-TO-END PATIENT INTAKE SOLUTION

7

Real-time Integration

Electronic Medical Record Practice Management System Practice Data Warehouses APIs Payment Networks Payers Telehealth Vendors

slide-8
SLIDE 8

THE PHREESIA PLATFORM

Robust analytic tools Commitment to privacy and security Reliable and scalable platform Real-time integration with leading PMs and EMRs

Patient Intake Platform

Appointments

Online appointment requests Referrals Appointments queue to track requests

Revenue Cycle

Insurance verification POS payments Card on file Payment plans Online payments

Clinical Support

Clinical screening tools and PROs for 25+ specialties Behavioral health screenings for primary care

Patient Activation Registration

Social determinants

  • f health screening

Mobile PhreesiaPads Consent management Payment assurance

8

Patient surveys Branded patient announcements Health campaigns Automated self- scheduling

Flexible APIs

8

Intake Workflows Arrivals Kiosks Typical entry-level package Patient chat

Life Sciences

Patient Connect Patient Insights Advanced Analytics

slide-9
SLIDE 9

OUR CURRENT AMBULATORY-BASED ADDRESSABLE MARKET

TAM of ~$7B

Source: (1) Kaiser Family Foundation, BLS Data, American Association of Nurse Practitioners, National Commission of Certification of Physician Assistants - assumes ~1,005,000 total physicians , with ~75% in non-acute care setting and 100% taking appointments; ~165,000 NPs, with ~85% in non-acute care setting and ~55% taking appointments; 90,000 PAs, with ~60% in non-acute care setting and ~65% taking appointments; (2) CMS, includes out-of-pocket spending for physician, clinical and other professional services; (3) ZS Associates, projected spending in point-of-care marketing in pharma (2014 – 2020)

~890K addressable providers1

in United States

Subscription-Based Revenue

$4.3B

$91B addressable out-of-pocket2

in United States

Consumer-Related Transaction And Payment Processing Fees

$2.2B

Life Sciences DTC point-of-care marketing spend3

$750M

9

Current addressable market does not include acute care

~780K active physicians ~77K nurse practitioners ~35K physician assistants

slide-10
SLIDE 10

SCALABLE FROM SMALL BUSINESSES TO LARGE ENTERPRISES

10

Serving ~1,600 healthcare provider organizations 25+ medical specialties of varying sizes Serving 13 of the top 20 global pharma companies

Providers Life Sciences

Physician groups Health systems Pharma manufacturers ~40 life sciences brands

  • Top 3 global pharma company
  • Top 3 global biotech company
  • Top 5 diabetes pharma

manufacturer

  • Top 5 oncology pharma

manufacturer

z

slide-11
SLIDE 11

In its annual “Best in KLAS: Software and Services” report, KLAS named Phreesia the 2020 Best in KLAS for Patient intake Management, based on survey data from provider groups on areas such as integration, implementation support and overall customer satisfaction. This is the second year that KLAS has named a top patient intake solution. Phreesia was also the top-ranked solution last year.

Phreesia Is the 2020 Best in KLAS Patient Intake Management Solution

11

slide-12
SLIDE 12

MULTIPLE GROWTH OPPORTUNITIES

12

  • Direct sales model
  • Acute care market in

early innings

  • Focus on larger

providers

  • Additional providers

within existing clients

  • New sites
  • New providers

within existing sites

  • Proven ability to

continuously innovate

  • Appointments,

Cost Estimation and Mobile

  • Upsell new

applications

  • New applications

and new and larger clients highly scalable on existing platform

  • Adj. EBITDA positive

in FY19 and FY20

  • Focus on growing

partnerships (i.e. PM, EHR, Life Sciences, R1)

  • Vital Score

acquisition completed in FY19

Land new clients Grow footprint within existing clients Cross-sell new applications to existing clients Margin expansion through scale Partnerships and M&A

slide-13
SLIDE 13

WATCH THE VIDEO BY CLICKING BELOW

13

slide-14
SLIDE 14

Financial Overview

14

slide-15
SLIDE 15

FINANCIAL PERFORMANCE HIGHLIGHTS

15

  • Large and growing addressable market of ~$7B
  • Expansion from additional providers from both existing and new Clients
  • Additional revenue from product innovations sold to existing clients
  • Strong visibility into revenue at the beginning of the fiscal period based on contracted business
  • 80%+ revenue from recurring monthly subscriptions and re-occurring payment processing fees
  • Contracts typically 1-year in length, with ~90% of provider client contracts renewing each year
  • Strong financial discipline with focus on profitable growth
  • Platform created for significant scale
  • Low marginal cost to support new providers
  • Stable recurring revenue and contribution margin from consistent Cohorts, net of churn

Growth Opportunities Highly Visible Revenue Attractive Economics

slide-16
SLIDE 16

SCALABLE AND PREDICTABLE SOURCES OF REVENUE

16

  • Fees earned as % of processed patient payments
  • ~80%+ volume: Credit / debit transactions processed on

Phreesia payment facilitator model

  • Remaining volume: Cash, check and credit gateway

transactions to other payment processors

  • Includes base package and add-on applications
  • Majority of fees charged per provider per month (PPPM)

Subscription and related services1 Payment processing fees

  • Increase in payment volume from

patients of existing and new providers / clients

  • Increase in patient financial responsibility
  • New provider clients
  • Expansion within existing clients
  • New products and applications

37% 45%

REVENUE MODEL DRIVERS FY20 % REV

  • Sale of targeted digital marketing solutions to patients
  • Contract duration typically 12 months
  • Guaranteed # of engagements with target audience
  • Fees charged per brand engagement

Life Sciences

  • New life sciences clients
  • Expansion within existing clients
  • Purposeful controlled growth
  • Investment in new data and analytics

products represent upside potential

18%

1 In addition to subscription revenue, Phreesia generates certain fees from provider clients for professional services associated with implementation, travel and expense reimbursements, shipping and handling, sale of hardware

(PhreesiaPads and Arrivals Stations), on-site support and training

Strong visibility into revenue at the beginning of the fiscal period based on contracted business

Provider

slide-17
SLIDE 17

1,490 1,571 1,549 1,632 FY 19 FY 20 FQ1 20 FQ1 21

+5%

$4 $6 $24 $27

FQ1 20 FQ1 21

$19 $22 $81 $103

FY 19 FY 20

STRONG OPERATING AND FINANCIAL PERFORMANCE

17

TOTAL REVENUE ($M)

FY ended January 31

$100 $125

+25%

Provider Life Sciences

1 For a reconciliation to the nearest GAAP measure, please see slide 20

$28 $33 $3.5 $4.8 ($0.3) $1.5 FY 19 FY 20 FQ1 20 FQ1 21

  • ADJ. EBITDA ($M)1
  • AVG. NUMBER OF

PROVIDER CLIENTS

  • AVG. PROVIDER

REVENUE PER CLIENT ($K) $54,231 $65,486 FY 19 FY 20 $15,649 $16,735 FQ1 20 FQ1 21

+18% +5% +21% +7%

+27% +13%

slide-18
SLIDE 18

Appendix

18

slide-19
SLIDE 19

DETAILED INCOME STATEMENT

19

1 For a reconciliation to the nearest GAAP measure, please see slide 20

$M Fiscal year ended January 31, Three months ended April 30, FY 2019 FY 2020 Q1 2020 Q1 2021 Revenue: Subscription and Related Services Revenue $43.9 $56.4 $12.7 $15.6 Payment Processing Revenue 36.9 46.5 11.6 11.7 Total Provider Revenue $80.8 $102.9 $24.2 $27.3 Life Sciences $19.1 $21.9 $4.1 $6.1 Total Revenue $99.9 $124.8 $28.3 $33.4 % Growth 25% 25% 19% 18% Expenses: Cost of revenues (excl. depreciation and amortization) $15.1 $16.8 $4.0 $4.7 Payment Processing Expense 21.9 27.9 6.9 6.8 Sales and Marketing 26.4 32.4 7.7 9.4 Research and Development 14.3 18.6 4.3 5.0 General and Adminstrative 20.1 30.5 6.2 8.7 Depreciation 7.6 8.8 2.2 2.3 Amortization 4.0 5.2 1.2 1.4 Total Expenses $109.4 $140.1 $32.6 $38.4 Operating loss ($9.5) ($15.3) ($4.3) ($5.0) Operating Margin (9.5%) (12.3%) (15.0%) (14.9%) Other Income (Expense) ($0.0) ($1.0) (1.1) (0.7) Change in Fair Value of Warrant Liability (2.1) (3.3) (0.4) 0.0 Interest Income (Expense) (3.5) (2.4) (0.8) (0.3) Total Other Income (Loss) ($5.6) ($6.8) ($2.4) ($1.0) (Benefit From) Provision for Taxes 0.0 (1.8) 0.1 0.1 Net Income (Loss) ($15.1) ($20.3) ($6.7) ($6.1) Net Margin % (15.1%) (16.3%) (23.6%) (18.3%) Memo: Adjusted EBITDA 1 $3.5 $4.8 ($0.3) $1.5 % Margin 3.6% 3.8% (1.0%) 4.6%

slide-20
SLIDE 20

ADJUSTED EBITDA RECONCILIATION1

20

1 Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be

considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity

$M Fiscal year ended January 31, Three months ended April 30, FY 2019 FY 2020 Q1 2020 Q1 2021 Reconciliation to Adjusted EBITDA Net Income (Loss) ($15.1) ($20.3) ($6.7) ($6.1) Interest Income (Expense) 3.5 2.4 0.8 0.3 Depreciation and Amortization 11.6 13.9 3.4 3.6 Stock-Based Compensation Expense 1.4 6.2 0.6 2.9 (Benefit From) Provision for Taxes 0.0 (1.8) 0.1 0.1 Change in Fair Value of Warrant Liability 2.1 3.3 0.4 0.0 Other (Income) Expense 0.0 1.0 1.1 0.7 Adjusted EBITDA1 $3.5 $4.8 ($0.3) $1.5 Adjusted EBITDA Margin % 3.6% 3.8% (1.0%) 4.6%